Dosing of PEG-Asparaginase in Acute Lymphoblastic Leukemia in Older Adults

Dosing According to Clinical Evidence Guidelines

The National Comprehensive Cancer Network recommends a dose of 2,500 UI/m² for PEG-asparaginase, although reduced doses of 2,000 UI/m² or less are suggested for older adults due to a significantly elevated toxicity profile in this age group 1, 2
The American College of Clinical Oncology suggests that the USC/MSKCC trial, which used 2,000 UI/m² in adults aged 18-60, demonstrated that this dose was lower than the FDA-approved dose to reduce toxicity in adults 1, 2, 3, 4
The reduction in dose was implemented to adjust for differences in enzymatic activity between adults and children 1, 2

The National Comprehensive Cancer Network recommends initiating with conservative doses of 1,000-2,000 UI/m², with intervals of ≥4 weeks between doses 1, 2
The initial dose should be 1,000-2,000 UI/m² IV, with a minimum interval of ≥4 weeks between doses 1, 2
The maximum number of doses should be up to 6 total doses scheduled over the course of treatment 1, 2
Mandatory premedication with hydrocortisone for hypersensitivity prophylaxis, followed by 1-2 weeks of oral steroids, is recommended 1, 2

In the USC/MSKCC trial using 2,000 UI/m², patients received an average of 3.8 doses per patient, with only 45% completing the 6 scheduled doses 1, 2
20% of patients discontinued treatment due to toxicity 1, 2

The National Comprehensive Cancer Network suggests that pancreatitis is a criterion for permanent discontinuation, with an incidence of 1-2% of clinical pancreatitis grade ≥3 5, 6
For asymptomatic elevations (chemical pancreatitis), continued treatment with close monitoring is possible 5, 6

Close monitoring of amylase and lipase levels during and after each dose is recommended 5, 6